Other equities analysts have also issued research reports about the stock. Zacks Investment Research lowered shares of Alliqua BioMedical from a buy rating to a hold rating in a research report on Wednesday, August 16th. ValuEngine lowered shares of Alliqua BioMedical from a sell rating to a strong sell rating in a research report on Friday, June 2nd. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. Alliqua BioMedical presently has an average rating of Buy and an average price target of $1.13.
Shares of Alliqua BioMedical (NASDAQ:ALQA) opened at 0.3491 on Monday. Alliqua BioMedical has a one year low of $0.23 and a one year high of $0.95. The stock’s market cap is $17.49 million. The firm has a 50 day moving average of $0.32 and a 200 day moving average of $0.41.
Alliqua BioMedical (NASDAQ:ALQA) last posted its quarterly earnings data on Thursday, August 10th. The company reported ($0.09) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.14) by $0.05. Alliqua BioMedical had a negative net margin of 185.30% and a negative return on equity of 107.24%. The company had revenue of $5.52 million during the quarter, compared to analyst estimates of $5.01 million. During the same quarter last year, the firm posted ($0.22) EPS. The business’s revenue for the quarter was up 23.5% on a year-over-year basis. On average, equities research analysts predict that Alliqua BioMedical will post ($0.40) EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This report was posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this report on another website, it was illegally stolen and republished in violation of international copyright laws. The correct version of this report can be read at https://www.chaffeybreeze.com/2017/09/19/alliqua-biomedical-inc-alqa-receives-buy-rating-from-hc-wainwright.html.
Institutional investors and hedge funds have recently made changes to their positions in the business. KCG Holdings Inc. boosted its holdings in shares of Alliqua BioMedical by 777.7% in the first quarter. KCG Holdings Inc. now owns 525,077 shares of the company’s stock worth $265,000 after buying an additional 465,256 shares during the period. Renaissance Technologies LLC boosted its holdings in shares of Alliqua BioMedical by 54.2% in the first quarter. Renaissance Technologies LLC now owns 632,800 shares of the company’s stock worth $319,000 after buying an additional 222,400 shares during the period. Sabby Management LLC boosted its holdings in shares of Alliqua BioMedical by 93.7% in the first quarter. Sabby Management LLC now owns 2,131,050 shares of the company’s stock worth $1,076,000 after buying an additional 1,030,652 shares during the period. Finally, Perceptive Advisors LLC boosted its holdings in shares of Alliqua BioMedical by 120.3% in the first quarter. Perceptive Advisors LLC now owns 4,233,951 shares of the company’s stock worth $2,136,000 after buying an additional 2,312,000 shares during the period. Institutional investors own 21.68% of the company’s stock.
About Alliqua BioMedical
Alliqua BioMedical, Inc is a provider of advanced wound care solutions. The Company’s businesses include advanced wound care and contract manufacturing. The Company operates through its subsidiaries, such as AquaMed Technologies, Inc and Choice Therapeutics, Inc The Company is engaged in developing a suite of advanced wound care solutions that will enable surgeons, clinicians and wound care practitioners to address the challenges in chronic and acute wounds.
Receive News & Ratings for Alliqua BioMedical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alliqua BioMedical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.